Phase I/II, open-label trial of safety and immunogenicity of meningococcal (Groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents

Pediatric Infectious Disease Journal

Volumn 29, Issue 5, 2010, Pages 391-396

  Siberry, George K ^a   Williams, Paige L ^b   Lujan Zilbermann, Jorge ^c   Warshaw, Meredith G ^b   Spector, Stephen A ^d,e   Decker, Michael D ^f,g   Heckman, Barbara E ^h   Demske, Emily F ⁱ   Read, Jennifer S ^a   Jean Philippe, Patrick ^j   Kabat, William ^k   Nachman, Sharon ^l  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f SANOFI PASTEUR   (France)

^g VANDERBILT UNIVERSITY   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k CHILDREN'S MEMORIAL HOSPITAL   (United States)

^l STONY BROOK UNIVERSITY   (United States)

more..

Author keywords

Adolescent; HIV; Immunization; Meningococcal vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIUM ANTIBODY; CD4 ANTIGEN; DIPHTHERIA TOXOID; MENINGOCOCCUS VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DEMOGRAPHY; DRUG FATALITY; DRUG SAFETY; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RESISTANCE; INJECTION SITE PAIN; MENINGITIS; MENINGOCOCCOSIS; MENTAL DISEASE; NEISSERIA MENINGITIDIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS LOAD;

EID: 77951832065     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181c38f3b     Document Type: Article

References (26)

1. Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in children aged 2-10 years at increased risk for invasive menin-gococcal disease. MMWR. 2007;56:1265-1266.
2. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2005;54(RR-7):1-21.
3. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159:907-913.
4. CDC. Guillain-Barré Syndrome among recipients of Menactra meningo-coccal conjugate vaccine\United States, June-July 2005. MMWR. 2005; 54:1023-1025.
5. CDC. Update: Guillain-Barré Syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, June 2005-September 2006. MMWR. 2006;55:1120-1124.
6. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis. 2004;4: 510-518.
7. Abzug MJ, Pelton SI, Song LY et al; Pediatric AIDS Clinical Trials Group P1024 Protocol Team. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2006;25:920-929.
8. Abzug MJ, Song LY, Fenton T et al; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 Protocol Team. Pertussis booster vaccination in HIV-infected children receiving highly active anti-retroviral therapy. Pediatrics. 2007;120:e1190-e1202.
9. Weinberg A, Gona P, Nachman SA et al; Pediatric AIDS Clinical Trials Group 1008 Team. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis. 2006;193:302-311.
10. Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005;24:410-416.
11. Gibb D, Giacomelli A, Masters J, et al. Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Pediatr Infect Dis J. 1996;15:1097-1101.
12. Read JS, Frasch CE, Rich K et al; Women and Infants Transmission Study Group. The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Pediatr Infect Dis J. 1998;17:391-397.
13. Madhi SA, Petersen K, Khoosal M, et al. Reduced effectiveness of Hae-mophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J. 2002;21:315-321.
14. DAIDS Toxicity Grading Table. Available at: http://rcc.tech-res.com/tox- tables.htm.
15. Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals. 2000;28:193-197.
16. Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568-1573.
17. Moore DA, Benepal T, Portsmouth S, et al. Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clin Infect Dis. 2001;32:469-476.
18. Krogstad P, Lee S, Johnson G et al; Pediatric AIDS Clinical Trials Group 377 Study Team. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34:991-1001.
19. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningo-coccal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28:86-91.
20. Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 2001;19:1327-1346.
21. Pollard AJ, Ochnio J, Ho M, et al. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. Emerg Infect Dis. 2004;10:1812-1815.
22. Trotter C, Borrow R, Andrews N, et al. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 2003;21:1094-1098.
23. Ceyhan M, Yildirim I, Balmer P, et al. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and sero-group A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine. 2007;25:7233-7237.
24. Abzug MJ. Vaccination in the immunocompromised child: a probe of immune reconstitution. Pediatr Infect Dis J. 2009;28:233-236.
25. Siberry GK, Coller RJ, Henkle E, et al. Antibody response to hepatitis a immunization among human immunodeficiency virus-infected children and adolescents. Pediatr Infect Dis J. 2008;27:465-468.
26. Tarragó D, Casal J, Ruiz-Contreras J et al; Spanish Network Pneumococcus Study Group. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol. 2005;12:165-170.